Idioma:

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Ambrosini, Valentina ; Kunikowska, Jolanta ; Baudin, Eric ; Bodei, Lisa ; Bouvier, Catherine ; Capdevila, Jaume ; Cremonesi, Marta ; de Herder, Wouter W. ; Dromain, Clarisse ; Falconi, Massimo ; Fani, Melpomeni ; Fanti, Stefano ; Hicks, Rodney J. ; Kabasakal, Levent ; Kaltsas, Gregory ; Lewington, Val ; Minozzi, Silvia ; Cinquini, Michela ; Öberg, Kjell ; Oyen, Wim. J.G. ; O'Toole, Dermot ; Pavel, Marianne ; Ruszniewski, Philippe ; Scarpa, Aldo ; Strosberg, Jonathan ; Sundin, Anders ; Taïeb, David ; Virgolini, Irene ; Wild, Damian ; Herrmann, Ken ; Yao, James

European journal of cancer (1990), 2021-03, Vol.146 (7), p.56-73 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Autor: Ambrosini, Valentina ; Kunikowska, Jolanta ; Baudin, Eric ; Bodei, Lisa ; Bouvier, Catherine ; Capdevila, Jaume ; Cremonesi, Marta ; de Herder, Wouter W. ; Dromain, Clarisse ; Falconi, Massimo ; Fani, Melpomeni ; Fanti, Stefano ; Hicks, Rodney J. ; Kabasakal, Levent ; Kaltsas, Gregory ; Lewington, Val ; Minozzi, Silvia ; Cinquini, Michela ; Öberg, Kjell ; Oyen, Wim. J.G. ; O'Toole, Dermot ; Pavel, Marianne ; Ruszniewski, Philippe ; Scarpa, Aldo ; Strosberg, Jonathan ; Sundin, Anders ; Taïeb, David ; Virgolini, Irene ; Wild, Damian ; Herrmann, Ken ; Yao, James
Assuntos: Adrenal glands ; Animals ; Bioactive compounds ; Clinical trials ; Computed tomography ; Consensus ; Deoxyglucose ; Diagnostic systems ; Fluorine isotopes ; Gallium isotopes ; Gastrointestinal system ; Gastrointestinal tract ; Hormones ; Human health and pathology ; Humans ; Lesions ; Life Sciences ; Magnetic resonance imaging ; Medical imaging ; Medicine ; Metastases ; Metastasis ; Molecular imaging ; Molecular Imaging - methods ; Neoplasms ; Nervous system ; Neuroendocrine neoplasms ; Neuroendocrine tumors ; Neuroendocrine Tumors - diagnostic imaging ; Neuroendocrine Tumors - pathology ; Neuroendocrine Tumors - therapy ; Nuclear medicine ; Pancreas ; Paraganglioma ; Patients ; Peptides ; Pheochromocytoma ; Positron emission ; Positron emission tomography ; Precision medicine ; PRRT ; Radiation therapy ; Radioisotopes ; Radiopharmaceuticals - metabolism ; Radiopharmaceuticals - therapeutic use ; Receptors ; Signs and symptoms ; Somatostatin ; Tomography ; Tumors
É parte de: European journal of cancer (1990), 2021-03, Vol.146 (7), p.56-73
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
PMCID: PMC8903070
Joint last authors
VA, JK, SF, SM, and KH designed the study. SM and MiC performed the search, extracted data from retrieved studies, and measured consensus across Delphi rounds. VA, JK, SF, RJH, WO, and KH wrote the paper. VA, EB, LB, JC, MC, WDH, CD, MaF, MeF, RJH, LK, GK, VL, KÖ, DO, MP, PR, ASc, JS, ASu, DT, IV, DW, and JY, were all members of the expert panel, designed the study, contributed to the content of the study, and reviewed the paper. CB contributed the patients’ perspective.
Joint first authors
Contributors
Descrição: Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NETs). NETs form in cells that interact with the nervous system or in glands that produce hormones. These cells, called neuroendocrine cells, can be found throughout the body, but NETs are most often found in the abdomen, especially in the gastrointestinal tract. These tumours may also be found in the lungs, pancreas and adrenal glands. In addition to being rare, NETs are also complex and may be difficult to diagnose. Most NETs are non-functioning; however, a minority present with symptoms related to hypersecretion of bioactive compounds. NETs often do not cause symptoms early in the disease process. When diagnosed, substantial number of patients are already found to have metastatic disease. Several societies' guidelines address Neuroendocrine neoplasms (NENs) management; however, many issues are still debated, due to both the difficulty in acquiring strong clinical evidence in a rare and heterogeneous disease and the different availability of diagnostic and therapeutic options across countries. EANM Focus 3 reached consensus on employing 68gallium-labelled somatostatin analogue ([68Ga]Ga-DOTA-SSA)-based PET/CT with diagnostic CT or magnetic resonance imaging (MRI) for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal pheochromocytoma/paraganglioma and suspected paraganglioma. Consensus was reached on employing 18fluorine-fluoro-2-deoxyglucose ([18F]FDG) PET/CT in neuroendocrine carcinoma, G3 NET and in G1-2 NET with mismatched lesions (CT-positive/[68Ga]Ga-DOTA-SSA-negative). Peptide receptor radionuclide therapy (PRRT) was recommended for second line treatment for gastrointestinal NET with [68Ga]Ga-DOTA-SSA uptake in all lesions, in G1/G2 NET at disease progression, and in a subset of G3 NET provided all lesions are positive at [18F]FDG and [68Ga]Ga-DOTA-SSA. PRRT rechallenge may be used for in patients with stable disease for at least 1 year after therapy completion. An international consensus is not only a prelude to a more standardised management across countries but also serves as a guide for the direction to follow when designing new research studies. •[68Ga]Ga-DOTA-SSA PET/CT and diagnostic CT are the mainstay for NET diagnosis.•[18F]FDG in: G3 NET, NEC, CT-pos/SSA-neg lesions, rapidly progressive cases.•[68Ga]Ga-DOTA-SSA for suspected extra-adrenal localisation of PPGL.•PRRT is indicated at first progression of G1-G2 GEP NET and selected NET G3.•PRRT as second line for GI-NET, if there is sufficient uptake in all lesions.
Editor: England: Elsevier Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 3 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

England: Elsevier Ltd

Buscando em bases de dados remotas. Favor aguardar.